Who Sets the Agenda for Global Health?
In the past two decades, cross-border and international
health challenges together with their risks factors, have mobilized unmatched
attention and resources. Once led by a few United Nations organizations, global health has attracted
hundreds of new actors, ranging from public to private sector organizations
including foundations. With the plurality, comes the challenge to coordinate
international health work and avoid needless duplication and wastes. And the absence
of clear practice to set agenda, unveils a growing gulf between health needs
and where resources are spent.
What interests, values and mechanisms underpin global health
governance? In a recent article, Dr.
Devi Sridhar argues that, the complex manner of setting agenda,
‘’is a consequence of a general phenomenon in global health, where the nature
and type of funding dictates priorities[1]..’’ She calls the emerging trend
‘’multibi-funding:’’ donors increasingly
earmarked and channeled their support through traditional multilateral
organisations and new multi-stakeholder initiatives to specify diseases,
countries and regions of their interests.
The opaque manner in setting priorities runs counter to evidence-based
approach, a cornerstone in public health. Through the practise, donors,
including private foundations, cherry pick diseases that get attention and
support. As a consequence, much needed resources
are diverted away from where needs are greatest. For example, the Bill Gates funded Institute for Health Metrics and Evaluation estimates that in 2010, non-communicable
diseases— like cancer, diabetes and hypertension— the biggest killers, received
less than 3 percent of the 28 billion dollars international assistance to
health. In contrast, HIV/AIDS, malaria
and tuberculosis together attracted 31 percent of the overall global health resources. Donors tie their support to
specific programs within United Nations organizations like WHO, as well as channel a lion’s share of their contributions to vertical funds like the Global Fund to fight HIV/AIDS, Tuberculosis,
and Malaria and the Global Action for Vaccines and Immunization (GAVI).
Praise for the progress to achieve health MDGs,
disease-specific initiatives however, have added complexity, uncertainty and
even chaos to the business of global health. Their innovative decision-making
structures raise some important concerns about accountability and legitimacy. Whereas
Member States are the only vote holders in key United Nations organizations,
decision-making in global health initiatives is by a selected number of donors
and non-governmental organizations. Even though, total funds for health have
quadrupled over the years, allocation to priorities is unpredictable. Global
health initiatives with their specific mandates are funded entirely by voluntary
contributions. Intergovernmental health organizations, with their broad
mandates have witnessed an exponentially growth in their unpredictable non-core
budgets, as long-term, core funds remain flat.
The shift in funding channels has significant implications
for global health governance. What donors are unable to achieve in open-multilateral
forums, where each country has a vote, they turn to closed ‘’market places’’,
where money counts. As a consequence, short term gains are favored over coordinated efforts to address long-term health challenges. An even greater risks, is undermining core capacities of traditional
global health institutions, which rely on fixed, predictable, long-term funds
to collate and disseminate vital information about diseases, a foundation of
global health research.
It remains unclear whether business will continue as usual,
at least in the short-term. Health appears to have buck a downward trend of
cuts to international development work. Funding has recovered to
pre-crisis levels, perhaps dissipating the urgency to reform, introduced by the global
financial. Emerging economies are reluctant to use the
power of their purse to shake up the status quo, too.
[1] Sridhar
D (2012) Who Sets the Global Health Research Agenda? The Challenge of Multi-Bi
Financing. PLoS Med 9(9): e1001312.
doi:10.1371/journal.pmed.1001312
Comments
Post a Comment